Financing-related issues and difficulties for Canadian biotechnology companies
by Michel Y. Bergeron, Lawrence Kryzanowski, Paul Beaulieu, Yoser Gadoum
International Journal of Biotechnology (IJBT), Vol. 3, No. 3/4, 2001

Abstract: Based on in-depth interviews with a large sample of company executives, this paper presents the financing-related issues and difficulties facing Canadian biotechnology companies in the biopharmaceutical, agbiotech, and bio-environmental industrial segments. The findings of this study lead to a series of unresolved concerns that require further thought, information gathering, and analysis. Some of these concerns are whether or not suppliers of funds in Canada have substantially different risk tolerances than suppliers in the USA, and whether or not the level of technical knowledge and sophistication of personnel in the providers of capital to the biotechnology sector is adequate. We provide some suggested courses of action for addressing these concerns in more depth.

Online publication date: Sun, 13-Jul-2003

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com